SCYX
SCYNEXIS, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$42M
5Y Perf.-87.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SCYX vs ATXS
Revenue, margins, valuation, and 5-year total return — side by side.
ATXS
Astria Therapeutics, Inc.
Biotechnology
Market Cap$718M
5Y Perf.-64.9%
SCYX vs ATXS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SCYX | ATXS |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $42M | $718M |
| Revenue (TTM) | $21M | $706K |
| Net Income (TTM) | $-9M | $-124M |
| Gross Margin | 9.5% | 100.0% |
| Operating Margin | -77.9% | -193.4% |
| Total Debt | $2M | $5M |
| Cash & Equiv. | $21M | $60M |
SCYX vs ATXS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SCYX
ATXS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SCYNEXIS, Inc. (SCYX) | 100 | 12.7 | -87.3% |
| Astria Therapeutics… (ATXS) | 100 | 35.1 | -64.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SCYX vs ATXS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SCYX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Astria Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SCYX
SCYNEXIS, Inc.
The Income Pick
SCYX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.78
- Rev growth 449.9%, EPS growth 61.4%, 3Y rev CAGR 59.4%
- Lower volatility, beta 0.78, Low D/E 4.4%, current ratio 7.04x
Best for: income & stability and growth exposure
ATXS
Astria Therapeutics, Inc.
The Long-Run Compounder
ATXS is the clearest fit if your priority is long-term compounding.
- -95.5% 10Y total return vs SCYX's -97.6%
- +184.6% vs SCYX's -0.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SCYX | 449.9% revenue growth vs ATXS's -21.7% |
| Quality / Margins | SCYX | -41.8% margin vs ATXS's -175.7% |
| Stability / Safety | SCYX | Beta 0.78 vs ATXS's 1.32 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXS | +184.6% vs SCYX's -0.4% |
| Efficiency (ROA) | SCYX | -14.4% ROA vs ATXS's -45.6%, ROIC -28.2% vs -50.3% |
SCYX vs ATXS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
SCYX vs ATXS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSCYXLAGGINGATXS
ATXSAstria Therapeutics, …
1leads
SCYXSCYNEXIS, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ATXSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SCYX4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SCYX6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ATXS5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SCYX leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SCYX is the larger business by revenue, generating $21M annually — 29.2x ATXS's $706,000. SCYX is the more profitable business, keeping -41.8% of every revenue dollar as net income compared to ATXS's -175.7%.
| Metric | SCYXSCYNEXIS, Inc. | ATXSAstria Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $21M | $706,000 |
| EBITDAEarnings before interest/tax | $11M | -$134M |
| Net IncomeAfter-tax profit | -$9M | -$124M |
| Free Cash FlowCash after capex | -$5M | -$120M |
| Gross MarginGross profit ÷ Revenue | +9.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -77.9% | -193.4% |
| Net MarginNet income ÷ Revenue | -41.8% | -175.7% |
| FCF MarginFCF ÷ Revenue | -25.6% | -170.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +3.3% | -27.9% |
SCYX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — SCYX and ATXS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SCYXSCYNEXIS, Inc. | ATXSAstria Therapeuti… |
|---|---|---|
| Market CapShares × price | $42M | $718M |
| Enterprise ValueMkt cap + debt − cash | $23M | $664M |
| Trailing P/EPrice ÷ TTM EPS | -5.63x | -7.49x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.02x | — |
| Price / BookPrice ÷ Book value/share | 0.97x | 2.21x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SCYX and ATXS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SCYX leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
SCYX delivers a -19.0% return on equity — every $100 of shareholder capital generates $-19 in annual profit, vs $-53 for ATXS. ATXS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SCYX's 0.04x. On the Piotroski fundamental quality scale (0–9), SCYX scores 5/9 vs ATXS's 1/9, reflecting solid financial health.
| Metric | SCYXSCYNEXIS, Inc. | ATXSAstria Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -19.0% | -53.2% |
| ROA (TTM)Return on assets | -14.4% | -45.6% |
| ROICReturn on invested capital | -28.2% | -50.3% |
| ROCEReturn on capital employed | -26.8% | -39.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 |
| Debt / EquityFinancial leverage | 0.04x | 0.02x |
| Net DebtTotal debt minus cash | -$19M | -$54M |
| Cash & Equiv.Liquid assets | $21M | $60M |
| Total DebtShort + long-term debt | $2M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -20.98x | — |
SCYX leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ATXS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATXS five years ago would be worth $10,697 today (with dividends reinvested), compared to $1,393 for SCYX. Over the past 12 months, ATXS leads with a +184.6% total return vs SCYX's -0.4%. The 3-year compound annual growth rate (CAGR) favors ATXS at -0.1% vs SCYX's -31.5% — a key indicator of consistent wealth creation.
| Metric | SCYXSCYNEXIS, Inc. | ATXSAstria Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +49.8% | -2.4% |
| 1-Year ReturnPast 12 months | -0.4% | +184.6% |
| 3-Year ReturnCumulative with dividends | -67.9% | -0.4% |
| 5-Year ReturnCumulative with dividends | -86.1% | +7.0% |
| 10-Year ReturnCumulative with dividends | -97.6% | -95.5% |
| CAGR (3Y)Annualised 3-year return | -31.5% | -0.1% |
ATXS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SCYX and ATXS each lead in 1 of 2 comparable metrics.
Risk & Volatility
SCYX is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than ATXS's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATXS currently trades 94.7% from its 52-week high vs SCYX's 73.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SCYXSCYNEXIS, Inc. | ATXSAstria Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 1.32x |
| 52-Week HighHighest price in past year | $1.31 | $13.29 |
| 52-Week LowLowest price in past year | $0.56 | $3.69 |
| % of 52W HighCurrent price vs 52-week peak | +73.1% | +94.7% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 46.1 |
| Avg Volume (50D)Average daily shares traded | 571K | 1.6M |
Evenly matched — SCYX and ATXS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SCYXSCYNEXIS, Inc. | ATXSAstria Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $19.40 |
| # AnalystsCovering analysts | — | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SCYX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ATXS leads in 1 (Total Returns). 2 tied.
Best OverallSCYNEXIS, Inc. (SCYX)Leads 2 of 6 categories
Loading custom metrics...
SCYX vs ATXS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SCYX or ATXS a better buy right now?
Analysts rate Astria Therapeutics, Inc.
(ATXS) a "Hold" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SCYX or ATXS?
Over the past 5 years, Astria Therapeutics, Inc.
(ATXS) delivered a total return of +7. 0%, compared to -86. 1% for SCYNEXIS, Inc. (SCYX). Over 10 years, the gap is even starker: ATXS returned -95. 5% versus SCYX's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SCYX or ATXS?
By beta (market sensitivity over 5 years), SCYNEXIS, Inc.
(SCYX) is the lower-risk stock at 0. 78β versus Astria Therapeutics, Inc. 's 1. 32β — meaning ATXS is approximately 69% more volatile than SCYX relative to the S&P 500. On balance sheet safety, Astria Therapeutics, Inc. (ATXS) carries a lower debt/equity ratio of 2% versus 4% for SCYNEXIS, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SCYX or ATXS?
On earnings-per-share growth, the picture is similar: SCYNEXIS, Inc.
grew EPS 61. 4% year-over-year, compared to 30. 6% for Astria Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SCYX or ATXS?
SCYNEXIS, Inc.
(SCYX) is the more profitable company, earning -41. 8% net margin versus -175. 7% for Astria Therapeutics, Inc. — meaning it keeps -41. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SCYX leads at -78. 0% versus -193. 4% for ATXS. At the gross margin level — before operating expenses — ATXS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SCYX or ATXS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SCYX or ATXS better for a retirement portfolio?
For long-horizon retirement investors, SCYNEXIS, Inc.
(SCYX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (SCYX: -97. 6%, ATXS: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SCYX and ATXS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SCYX is a small-cap high-growth stock; ATXS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.